ENGN
enGene Holdings Inc

1,197
Mkt Cap
$576.04M
Volume
146,215.00
52W High
$11.14
52W Low
$2.65
PE Ratio
-4.71
ENGN Fundamentals
Price
$8.53
Prev Close
$8.92
Open
$9.01
50D MA
$7.83
Beta
0.30
Avg. Volume
3.45M
EPS (Annual)
-$1.46
P/B
2.27
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
enGene (ENGN) Projected to Post Earnings on Thursday
enGene (NASDAQ:ENGN) will be releasing its Q4 2025 earnings before the market opens on Thursday, December 18. (View Earnings Report at...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
enGenes Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected...
Business Wire·10d ago
News Placeholder
enGene (NASDAQ:ENGN) Trading Up 6.9% - Should You Buy?
enGene (NASDAQ:ENGN) Trading 6.9% Higher - Here's What Happened...
MarketBeat·15d ago
News Placeholder
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of "Moderate Buy" by Brokerages
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat reports. One research...
MarketBeat·21d ago
News Placeholder
Leerink Partnrs Reduces Earnings Estimates for enGene
enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Leerink Partnrs decreased their FY2030 earnings estimates for shares of enGene in a research report issued to clients and investors on Thursday...
MarketBeat·24d ago
News Placeholder
Leerink Partnrs Brokers Reduce Earnings Estimates for enGene
enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for shares of enGene in a report released on Tuesday...
MarketBeat·27d ago
News Placeholder
Leerink Partnrs Estimates enGene FY2030 Earnings
enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Research analysts at Leerink Partnrs issued their FY2030 earnings estimates for shares of enGene in a research report issued on Tuesday, November...
MarketBeat·28d ago
News Placeholder
enGene (NASDAQ:ENGN) Price Target Raised to $19.00 at Morgan Stanley
Morgan Stanley lifted their price target on shares of enGene from $18.00 to $19.00 and gave the stock an "overweight" rating in a research note on Wednesday...
MarketBeat·29d ago
News Placeholder
enGene (NASDAQ:ENGN) Given New $21.00 Price Target at Citizens Jmp
Citizens Jmp boosted their target price on shares of enGene from $18.00 to $21.00 and gave the stock a "market outperform" rating in a report on Wednesday...
MarketBeat·29d ago
News Placeholder
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering...
Business Wire·30d ago

Latest ENGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.